12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pixuvri pixantrone regulatory update

Cell Therapeutics said the U.K.'s NICE will meet on Sept. 11 to consider the biotech's recently approved patient access scheme (PAS) on the cost-effectiveness of Pixuvri pixantrone to treat multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma - its approved indication. At the...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >